So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021.

Fourth Quarter 2021 Financial Highlights

  • Total revenues were RMB449.5 million (US$70.5 million1), an increase of 5.9% from RMB424.6 million in the same period of 2020, in line with our previous guidance.
  • Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.
  • Non-GAAP net income attributable to So-Young International Inc.2 was RMB62.9 million (US$9.9 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB63.1 million in the fourth quarter of 2020.

Fourth Quarter 2021 Operational Highlights

  • Average mobile MAUs were 7.4 million, compared with 8.9 million in the fourth quarter of 2020.
  • Number of paying medical service providers on So-Young’s platform were 5,327, an increase of 12.2% from 4,746 in the fourth quarter of 2020.
  • Number of medical service providers subscribing to information services on So-Young’s platform were 2,085, compared with 2,239 in the fourth quarter of 2020.
  • Total number of users purchasing reservation services were 159.9 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB532.7 million.

Fiscal Year 2021 Financial Highlights

  • Total revenues were RMB1,692.5 million (US$265.6 million) in the full year 2021, an increase of 30.7% from RMB1,295.0 million in the prior year.
  • Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million) in the full year 2021, compared with a net income attributable to So-Young International Inc. of RMB5.8 million in the prior year.
  • Non-GAAP net income attributable to So-Young International Inc. was RMB139.5 million (US$21.9 million) in the full year 2021, an increase of 42.4% from RMB98.0 million in the prior year.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “We achieved 30.7% revenue growth in 2021 with total revenues at RMB1.7 billion despite the weaker-than-normal consumer sentiment as a result of the COVID-19 pandemic. We continuously strengthened operating management ability and branding digital support for medical service providers on our platform to improve their acquisition efficiency and customer experience. As a result, the number of paying medical service providers on our platform were 6,634 in 2021, up 19.1% from 5,570 year-over-year. The average mobile MAUs reached 8.5 million in 2021, up 18.7% year-over-year.”

Mr. Jin continued, “In 2021, we were working to reinforce the trust with consumers, meeting medical and aesthetic consumer demand from the different levels to make efficient decisions. On the business side, we solidified our competitive advantage and completed the acquisition of Wuhan Miracle to create a competitive moat on non-surgical side. Stepping into 2022, we are committed to local aesthetic services to reaffirm our leadership position and building aesthetic supply chain ecosystem to ensure the management and control of product authenticity and supervision for customers.”

Mr. Min Yu, “We’re pleased to conclude 2021 with a solid revenue growth, which was very encouraging. Looking ahead, while exploring new business, we will maintain a healthy and sustainable revenue growth and earning in the long term as we continuously improve our operating efficiency and effectively control cost.”

Fourth Quarter 2021 Financial Results

Revenues

Total revenues were RMB449.5 million (US$70.5 million), an increase of 5.9% from RMB424.6 million in the same period of 2020. The increase was primarily due to the consolidated revenues of RMB63.8 million (US$10.0 million) in the fourth quarter of 2021 from Wuhan Miracle Laser Systems, Inc. (“Wuhan Miracle”), which was acquired on July 23, 2021.

  • Information services and other revenues were RMB344.3 million (US$54.0 million), an increase of 2.5% from RMB335.9 million in the same period of 2020. The increase was primarily due to an increase in average revenue per paying medical service provider.
  • Reservation services revenues were RMB41.4 million (US$6.5 million), a decrease of 53.4% from RMB88.7 million in the same period of 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.
  • Sales of equipment and maintenance services revenues were RMB63.8 million (US$10.0 million), from Wuhan Miracle, our newly acquired subsidiary.

Cost of Revenues

Cost of revenues were RMB127.1 million (US$19.9 million), an increase of 99.8% from RMB63.6 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of the costs of Wuhan Miracle. Cost of revenues included share-based compensation expenses of RMB5.8 million (US$0.9 million) during the fourth quarter of 2021, compared with RMB5.0 million in the corresponding period of 2020.

Operating Expenses

Total operating expenses were RMB371.9 million (US$58.4 million), an increase of 12.3% from RMB331.2 million in the fourth quarter of 2020.

  • Sales and marketing expenses were RMB152.7 million (US$24.0 million), a decrease of 27.4% from RMB210.4 million in the fourth quarter of 2020. The decrease was primarily due to a decrease in expenses associated with branding and marketing activities. Sales and marketing expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB3.7 million (US$0.6 million), compared with RMB2.2 million in the corresponding period of 2020.
  • General and administrative expenses were RMB85.9 million (US$13.5 million), an increase of 72.1% from RMB49.9 million in the fourth quarter of 2020. The increase was primarily due to the consolidation of Wuhan Miracle. General and administrative expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB32.3 million (US$5.1 million), compared with RMB11.3 million in the corresponding period of 2020.
  • Research and development expenses were RMB67.5 million (US$10.6 million), a decrease of 4.8% from RMB70.9 million in the fourth quarter of 2020. The decrease was primarily due to the decrease of payroll costs. Research and development expenses for the fourth quarter of 2021 included share-based compensation expenses of RMB7.1 million (US$1.1 million), compared with RMB5.9 million in the corresponding period of 2020.
  • Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).

Income Tax Expenses

Income tax expenses were RMB10.1 million (US$1.6 million), compared with RMB13.0 million in the same period of 2020.

Net income/(loss) attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB27.7 million (US$4.4 million), compared with a net income attributable to So-Young International Inc. of RMB38.6 million in the fourth quarter of 2020.

Non-GAAP net income attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB62.9 million (US$9.9 million), compared with RMB63.1 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2020.

Basic and Diluted Earnings/(Loss) per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.26 (US$0.04) and RMB0.26 (US$0.04), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.36 and RMB0.35, respectively, in the same period of 2020.

Fiscal Year 2021 Financial Results

Revenues

Total revenues were RMB1,692.5 million (US$265.6 million), an increase of 30.7% from RMB1,295.0 million in fiscal year 2020.

  • Information services and other revenues were RMB1,304.5 million (US$204.7 million), an increase of 35.6% from RMB962.1 million in fiscal year 2020. The increase was primarily attributable to an increase in average revenue per medical service provider.
  • Reservation services revenues were RMB276.1 million (US$43.3 million), a decrease of 17.1% from RMB332.9 million in fiscal year 2020. The decrease was primarily due to the weaker-than-normal consumer sentiment and containment measures as a result of the resurgence of COVID-19, which had a negative impact on our operations in several cities across the country.
  • Sales of equipment and maintenance services revenues were RMB112.0 million (US$17.6 million), from Wuhan Miracle, our newly acquired subsidiary.

Cost of Revenues

Cost of revenues were RMB327.9 million (US$51.5 million), an increase of 54.5% from RMB212.2 million in fiscal year 2020. The increase was primarily due to the consolidation of Wuhan Miracle. In addition, cost of revenues for fiscal year 2021 included share-based compensation expenses of RMB18.8 million (US$2.9 million) compared to RMB18.3 million in fiscal year 2020.

Operating Expenses

Total operating expenses were RMB1,397.1 million (US$219.2 million), an increase of 22.6% from RMB1,139.5 million in fiscal year 2020.

  • Sales and marketing expenses were RMB792.5 million (US$124.4 million), an increase of 9.1% from RMB726.3 million in fiscal year 2020. The increase was primarily due to an increase in expenses associated with marketing campaigns and user acquisition initiatives and the consolidation of Wuhan Miracle. Sales and marketing expenses for fiscal year 2021 included share-based compensation expenses of RMB9.8 million (US$1.5 million), compared to RMB6.7 million in fiscal year 2020.
  • General and administrative expenses were RMB252.2 million (US$39.6 million), an increase of 37.1% from RMB184.0 million in fiscal year 2020. This was primarily due to an increase in personnel related expenses and the consolidation of Wuhan Miracle. General and administrative expenses for 2021 included share-based compensation expenses of RMB56.7 million (US$8.9 million), compared to RMB46.0 million in fiscal year 2020.
  • Research and development expenses were RMB286.6 million (US$45.0 million), an increase of 25.0% from RMB229.2 million in fiscal year 2020. The increase was primarily attributable to an increase in personnel related expenses. Research and development expenses for 2021 included share-based compensation expenses of RMB20.9 million (US$3.3 million), compared to RMB21.1 million in fiscal year 2020.
  • Impairment of goodwill and intangible assets was RMB65.9 million (US$10.3 million), representing the amount by which the carrying amount of certain asset exceeds their fair value in relation to the acquiring subsidiary, based on an annual goodwill and intangible assets impairment assessment. The impairment of goodwill was RMB48.5 million (US$7.6 million) and the impairment of intangible assets was RMB17.4 million (US$2.7 million).

Income Tax (Expenses)/Benefit

Income tax expenses were RMB21.2 million (US$3.3 million), compared with an income tax benefit of RMB4.8 million in fiscal year 2020. The income tax benefit was derived from a change in the preferential income tax rate of one of So-Young’s subsidiaries, which resulted in a refund of RMB16.4 million for tax paid in previous periods.

Net income/(loss) attributable to So-Young International Inc.

Net loss attributable to So-Young International Inc. was RMB8.4 million (US$1.3 million), compared with a net income attributable to So-Young International Inc. of RMB5.8 million in fiscal year 2020.

Non-GAAP net income attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc., was RMB139.5 million (US$21.9 million), compared with RMB98.0 million non-GAAP net income attributable to So-Young International Inc. in fiscal year 2020.

Basic and Diluted Earnings per ADS

Basic and diluted loss per ADS attributable to ordinary shareholders were RMB0.08 (US$0.01) and RMB0.08 (US$0.01), respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB0.05 and RMB0.05 in fiscal year 2020.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of December 31, 2021, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,756.0 million (US$275.6 million), compared with RMB2,676.0 million as of December 31, 2020.

Business Outlook

For the first quarter of 2022, So-Young expects its total revenues to be between RMB290 million (US$46.0 million) and RMB300 million (US$47.0 million), representing a 19.4% to 16.6% decrease from the same period in 2021. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, and customer demand, particularly in view of the potential impact of the COVID-19, the effects of which are difficult to analyze and predict, which are all subject to changes.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses and impairment of goodwill and intangible assets from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. The impairment of goodwill and intangible assets are considered unusual charges as the company does not have frequent such charges. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses and impairment of goodwill and intangible assets in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

About So-Young International Inc.So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor RelationsMs. Vivian XuPhone: +86-10-8790-2012E-mail: ir@soyoung.com

Christensen

In ChinaMr. Eric YuanPhone: +86-10-5900-1548E-mail: Eyuan@christensenir.com

In USMs. Linda BergkampPhone: +1-480-614-3004Email: lbergkamp@christensenir.com

SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except for share and per share data)
 
  As of  
  December 31,2020   December 31,2021   December 31,2021    
  RMB   RMB   US$    
Assets              
Current assets:              
Cash and cash equivalents 1,127,055   1,331,968   209,015    
Restricted cash and term deposits 21,865   15,119   2,373    
Trade receivables 52,871   54,829   8,604    
Inventories, net -   91,812   14,407    
Receivables from online payment platforms 16,182   18,864   2,960    
Amounts due from related parties 7,764   14,038   2,203    
Term deposits and short-term investments 1,527,088   408,946   64,173    
Prepayment and other current assets 43,190   91,842   14,412    
Total current assets 2,796,015   2,027,418   318,147    
Non-current assets:              
Long-term investments 166,100   252,500   39,623    
Intangible assets 60,029   193,955   30,436    
Goodwill 48,500   540,693   84,847    
Property and equipment, net 29,830   124,576   19,549    
Deferred tax assets 55,520   47,520   7,457    
Operating lease right-of-use assets 120,140   95,609   15,003    
Other non-current assets 15,878   48,097   7,547    
Total non-current assets 495,997   1,302,950   204,462    
Total assets 3,292,012   3,330,368   522,609    
               
Liabilities              
Current liabilities:              
Taxes payable 60,070   48,571   7,622    
Contract liabilities 135,385   139,155   21,836    
Salary and welfare payables 95,758   103,624   16,261    
Amounts due to related parties 2,404   681   107    
Accrued expenses and other current liabilities 237,785   376,841   59,136    
Operating lease liabilities-current 39,468   43,529   6,831    
Total current liabilities 570,870   712,401   111,793    
Non-current liabilities:              
Operating lease liabilities-non current 93,044   62,356   9,785    
Deferred tax liabilities 8,522   38,577   6,054    
Total non-current liabilities 101,566   100,933   15,839    
Total liabilities 672,436   813,334   127,632    
               
Mezzanine equity              
Redeemable non-controlling interests 23,205   -   -    
Total mezzanine equity 23,205   -   -    
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)
(All amounts in thousands, except for share and per share data, unless otherwise noted)
 
Shareholders’ equity:            
Treasury stock -     (217,712 )   (34,164 )  
Class A Ordinary shares (US$ 0.0005 par value; 750,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 70,212,159 shares issued and outstanding as of December 31, 2020; 71,736,059 and 69,092,367 shares issued and outstanding as of December 31, 2021, respectively) 224     230     36    
Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2020 and December 31, 2021; 12,000,000 shares issued and outstanding as of December 31, 2020 and December 31, 2021) 37     37     6    
Additional paid-in capital 2,892,268     2,999,562     470,697    
Statutory reserves 10,562     20,331     3,190    
Accumulated deficit (254,228 )   (272,368 )   (42,740 )  
Accumulated other comprehensive loss (52,492 )   (83,891 )   (13,164 )  
Total So-Young International Inc. shareholders’ equity 2,596,371     2,446,189     383,861    
             
Non-controlling interests -     70,845     11,116    
             
Total shareholders’ equity 2,596,371     2,517,034     394,977    
             
Total liabilities, mezzanine equity and shareholders’ equity 3,292,012     3,330,368     522,609    
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
 
  For the Three Months Ended   For the Fiscal Year Ended
  December 31,2020   December 31,2021   December 31,2021   December 31,2020   December 31,2021   December 31,2021  
  RMB   RMB   US$   RMB   RMB   US$  
                         
Revenues                        
Information services and others 335,911     344,315     54,030     962,089     1,304,455     204,697    
Reservation services 88,724     41,372     6,493     332,899     276,052     43,320    
Sales of equipment and maintenance services -     63,836     10,017     -     111,956     17,568    
Total revenues 424,635     449,523     70,540     1,294,988     1,692,463     265,585    
Cost of revenues (63,620 )   (127,090 )   (19,943 )   (212,206 )   (327,889 )   (51,453 )  
Gross profit 361,015     322,433     50,597     1,082,782     1,364,574     214,132    
Operating expenses:                        
Sales and marketing expenses (210,378 )   (152,656 )   (23,955 )   (726,297 )   (792,484 )   (124,358 )  
General and administrative expenses (49,888 )   (85,852 )   (13,472 )   (183,987 )   (252,214 )   (39,578 )  
Research and development expenses (70,920 )   (67,519 )   (10,595 )   (229,192 )   (286,567 )   (44,969 )  
Impairment of goodwill and intangible assets -     (65,879 )   (10,338 )   -     (65,879 )   (10,338 )  
Total operating expenses (331,186 )   (371,906 )   (58,360 )   (1,139,476 )   (1,397,144 )   (219,243 )  
Income/(loss) from operations 29,829     (49,473 )   (7,763 )   (56,694 )   (32,570 )   (5,111 )  
Other income/(expenses):                        
Investment income 3,130     927     145     13,599     8,931     1,401    
Interest income 6,753     3,654     573     39,669     19,328     3,033    
Exchange (losses)/gain (603 )   33     5     (1,118 )   (4,766 )   (748 )  
Impairment of long-term investment -     -     -     -     (17,850 )   (2,801 )  
Share of gain/(losses) of equity method investee 198     (746 )   (117 )   (4,279 )   (1,522 )   (239 )  
Others, net 11,407     2,208     346     8,916     12,044     1,890    
Income/(loss) before tax 50,714     (43,397 )   (6,811 )   93     (16,405 )   (2,575 )  
Income tax (expenses)/benefit (12,997 )   (10,145 )   (1,592 )   4,784     (21,231 )   (3,332 )  
Net income/(loss) 37,717     (53,542 )   (8,403 )   4,877     (37,636 )   (5,907 )  
Net loss attributable to noncontrolling interests 930     25,806     4,050     930     29,265     4,592    
Net income/(loss) attributable to So-Young International Inc. 38,647     (27,736 )   (4,353 )   5,807     (8,371 )   (1,315 )  
SO-YOUNG INTERNATIONAL INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)
(Amounts in thousands, except for share and per share data)
 
  For the Three Months Ended   For the Fiscal Year Ended
  December 31, 2020   December 31, 2021   December 31, 2021   December 31, 2020   December 31, 2021   December 31, 2021  
  RMB   RMB   US$   RMB   RMB   US$  
                         
Net income/(loss) per ordinary share                        
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - basic 0.47     (0.34 )   (0.05 )   0.07     (0.10 )   (0.02 )  
Net earnings/(loss) per ordinary share attributable to ordinary shareholder - diluted 0.46     (0.34 )   (0.05 )   0.07     (0.10 )   (0.02 )  
Net earnings/(loss) per ADS attributable to ordinary shareholders - basic (13 ADS represents 10 Class A ordinary shares) 0.36     (0.26 )   (0.04 )   0.05     (0.08 )   (0.01 )  
Net earnings/(loss) per ADS attributable to ordinary shareholders - diluted (13 ADS represents 10 Class A ordinary shares) 0.35     (0.26 )   (0.04 )   0.05     (0.08 )   (0.01 )  
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic* 81,904,047     81,304,182     81,304,182     81,534,991     81,680,504     81,680,504    
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted* 84,108,250     81,304,182     81,304,182     83,781,406     81,680,504     81,680,504    
                         
Share-based compensation expenses included in:                        
Cost of revenues (5,040 )   (5,830 )   (915 )   (18,327 )   (18,768 )   (2,945 )  
Sales and marketing expenses (2,183 )   (3,719 )   (584 )   (6,711 )   (9,808 )   (1,539 )  
General and administrative expenses (11,311 )   (32,259 )   (5,062 )   (46,001 )   (56,705 )   (8,898 )  
Research and development expenses (5,943 )   (7,106 )   (1,115 )   (21,131 )   (20,869 )   (3,275 )  

*         Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

SO-YOUNG INTERNATIONAL INC.
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands, except for share and per share data)
 
  For the Three Months Ended   For the Fiscal Year Ended
  December 31, 2020   December 31, 2021   December 31, 2021   December 31, 2020   December 31, 2021   December 31, 2021  
  RMB   RMB   US$   RMB   RMB   US$  
                         
GAAP income/(loss) from operations 29,829   (49,473 )   (7,763 )   (56,694 )   (32,570 )   (5,111 )  
Add back: Shared-based compensation expenses 24,477   48,914     7,676     92,170     106,150     16,657    
Add back: Impairment of goodwill and intangible assets -   65,879     10,338     -     65,879     10,338    
Non-GAAP income from operations 54,306   65,320     10,251     35,476     139,459     21,884    
                         
                         
GAAP Net income/(loss) attributable to So-Young International Inc. 38,647   (27,736 )   (4,353 )   5,807     (8,371 )   (1,315 )  
Add back: Shared-based compensation expenses 24,477   48,914     7,676     92,170     106,150     16,657    
Add back: Impairment of goodwill and intangible assets attributable to So-Young International Inc. -   41,748     6,551     -     41,748     6,551    
Non-GAAP Net income attributable to So-Young International Inc. 63,124   62,926     9,874     97,977     139,527     21,893    

_________________________

1 This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.3726 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on December 30, 2021.

2 Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses and impairment of goodwill and intangible assets attributable to So-Young International Inc. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.

So Young (NASDAQ:SY)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos So Young.
So Young (NASDAQ:SY)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos So Young.